Top of page Skip navigation

Innovation Workshops

Below you'll find a list of companies hosting Innovation Workshops on the days surrounding Genesis. Members, if you would like access to any of the workshop videos, please email

Monday 7 December: 

10:00-11:00 - The Power of Collaboration: When World-Leading Science Translates Into Business Success
Norwich Research Park is home to over 150 businesses who join a collaborative community of over 30,000 talented people. These businesses have achieved success by translating concepts developed from basic scientific research into viable innovative commercial propositions.

In this workshop you will find out how to collaborate with us, learn about our future development plans and hear from three ground-breaking Park-based businesses: Colorifix, Leaf Expression Systems and Iceni Diagnostics. They will showcase the role Norwich Research Park’s collaborative ethos plays in their success. Their work is changing lives and rethinking society, whether it’s through revolutionising the fashion industry with new technology to dye fabrics and reduce environmental impact, developing rapid testing for COVID-19 or using cutting edge plant-based technology to produce proteins and antigens for use in antiviral therapeutics and diagnostic testing. The workshop includes a live Q&A where you can pose your questions direct to these businesses and our Chief Executive David Parfrey.


11:30-12:30 - Bispecific Discovery Where Do We Start and Where Are We Going To?
Listeners will learn about single domain VHH antibodies, their application in bispecific antibodies and considerations for discovery projects.


13:30-14:30 - How a Successful Life Science Eco-system Helps Drive Business Growth
Nottingham has a long-standing and successful life-science sector that has been present in the city since the 1840’s with the creation of Boots. We’re a city of discoveries – Ibuprofen and the MRI scanner were invented in Nottingham – and we continue to be at the cutting edge of health innovation.

The Innovation Workshop will take a closer look at the ecosystem the city has in place to help the breakthrough companies of today grow and prosper. We will explore how fast-growing companies are able to tap into a wealth of support and experience as well as collaborate with our universities and businesses alike.

Our panel will help you understand how regional life-science clusters, like those in Nottingham, are able to provide the dedicated support fast-growing SMEs needs to become successful and continue to develop innovative solutions and products.

Tuesday 8 December: 

10:00-11:00 - Deal Management for Innovators (e.g. SMEs, Start-ups, Spin-outs, and Universities)
Innovation is the process by which ideas grow up to become products.  Innovators in the biopharmaceutical and biomedical fields face a long innovation cycle, a high risk of failure, and nearly always need a development and go-to-market partner.  Therefore, innovators are at all times on a trajectory to a deal, whether it is fund-raising, licensing, acquiring, or selling.  Underpinning all this are various forms of intellectual property (IP).  In fact, for innovators it is the IP that carries the majority of the value of their growing assets.  In this workshop, using reference case studies, we will highlight the key stages in value creation for innovators, how to build commercial IP portfolios capable of supporting innovator businesses and deals, and demonstrate how sound IP valuation and deal structuring can be used to optimise transactions.


11:30-12:30 - How Much Data Should Be Included in a Patent Application? Lessons Learned From Regeneron Pharmaceuticals V. Kymab
Researchers are under pressure to publish and this needs to be carefully balanced against the timing of filling a robust patent application. This balance is especially important in the current climate, where research groups have had to limit their research activities due to COVID-19. Biotech specialist patent attorney and Appleyard Lees partner Barbara Fleck will discuss strategies for preparing patent applications and also consider lessons learned from a recent UK Supreme Court decision.


13:30-14:30 - The Challenges to Deliver a Vaccine 
Flanders is known as a vaccine development and production hub. In this innovation workshop, we will zoom in on how the different players such as pharmaceutical and logistics companies to government actors and research institutes play their part in the vaccine ecosystem in Flanders. How do they drive innovation and which lesson can we draw from this ecosystem?

The session will be hosted by Dr. Jan Wauters, Science and Technology at Flanders Investment & Trade. Dr Wauters will host a panel discussion with captains of industry:

  • Dr Jan Wauter – Technology Attaché for Flanders Investment & Trade as MC
  • Luc Debruyne – Strategic Advisor to the CEO of CEPI and former President of Global Vaccines at GSK
  • Danny Hendrikse – VP Intercompany Operations at Pfizer
  • Samuel Speltdoorn – Cargo Business Development Manager at Brussels Airport

The discussion will focus on the current challenges of getting a vaccines delivered during a pandemic, from producing, to shipping challenges and getting it to patients.


15:00-16:00 - What, Where and When – Creating the R&D Space for the Future
The availability of first class research facilities is a key factor in any region’s ability to grow its Life Sciences economy. The high cost of developing such space often deters developers from building speculatively, yet the demand has perhaps never been stronger with record breaking levels of investment being attracted by the sector in recent years. Some of the challenges remain constant in terms of planning processes, cost and aligning the plans with future demand some years later. The Covid-19 pandemic has also shone a bright light on a more diverse sector ranging across biomedical R&D, medical technology research and manufacturing needs as stakeholders seek to increase future resilience. This panel will discuss what types of R&D space, in which locations and on what timelines the developers and planning authorities should consider.

Wednesday 9 December: 

10:00-11:00 - Japan as a New Investment Target for Life Science Innovation
Following the recent EPA (Economic Partnership Agreement) between Japan and the UK, Japan is attracting more interest among international investors, especially for what concerns life-science innovation ventures. LINK-J (Life Science Innovation Network Japan), one of the most active Japanese life-science ecosystems partnering with One Nucleus, invites four leading Japanese startups to pitch their technologies at the Innovation Workshop.


11:30-12:30 - Never Let a Crisis Go to Waste - What the Pandemic Has Taught Us About Accelerating Our Products and Nailing Our Messaging
Milestones don't move. How can you meet them during a pandemic, and accelerate them afterwards? Covid has made comms crowded. How can you cut through the noise and make your messaging memorable to payers, patients and peers?   


13:30-14:30 - Preclinical & Early Phase Clinical Development: It's Not Simply a Box Ticking Exercise
Our VP of Early Development will be presenting with Leads to Development, our non-clinical collaborator for a discussion of early stage clinical development to help you plan your next clinical study.


15:00-16:00 - Loose Lips Sink IP Ships - What Not to Say at Genesis to Protect Your Intellectual Property
Genesis is a great place to talk to investors and potential commercial partners about your ideas and inventions but if you disclose too much too soon it could be a disaster. Patent Attorneys, Guy Brain and Kapil Tuladhar from J A Kemp will give you the expert view on what you should and shouldn’t say and do.


Friday 11 December: 

10:00-11:00 - Lifescience Industry News Spotlight Covid-19 Response and Resilience, How Industry Met the Challenge 
This session brings together a panel of industry experts from across the UK to discuss the impact that Covid-19 has had on the sector and how businesses will start the recovery. 


11:30-12:30 - Attracting Digital Skills to Life Sciences 
The increasing use of big data, AI and Machine Learning in Life Sciences R&D whilst creating huge opportunities for ever more precision and evidence-based treatments also brings with it the challenge of recruiting the appropriate levels of expertise to the sector to harness this exciting potential. There are many factors that influence anyone’s career choices and this session will discuss what Life Sciences can do in order to compete with other sectors in securing the digital skills supply it requires.


13:30-14:30 - Legal Workshop – Transformative Transactions (Private to Public)
Mills & Reeve will host a panel session talking through the process of taking a UK private company to Nasdaq: from initial considerations relating to the choice of market for listing, through the practicalities of implementing such a significant cross border transaction, to the regulatory requirements for maintaining a public listing.  The session will lean heavily on experience gained from Cambridge-based biotech F-star’s reverse merger with a Nasdaq listed entity, which Mills & Reeve advised on, and include panellists from F-star and Mintz Levin who advised on the US aspects of the transaction.



15:00-16:30 - Advanced Analytical Workflows for the Bio Industry
“Overview of HPLC and LCMS capabilities, modern analytical methods for Biopharma ” – Denis Calnan
An overview of the methods and workflows available to characterise the quality and safety of Biopharmaceuticals. Including HPLC , LCMS , data analysis and reporting Critical Quality Attributes.

“State of the art analytics for characterising key metabolites in Cell culture media” – Min Du
A Study using UHPLC MS in a robust , easy to use workflow to identify the key metabolites in Cell growth culture media data that can be used to optimize growth conditions and improve yields .

 “The power of Chromatography Workflows to better understand Biopharmaceuticals” - Ken Cook
A closer look at analytical methods including Quality attributes of Mabs and new advanced methods for analysing Oligonucleotides , a key component in Cell and Gene Therapy and Vaccine manufacturing.


Monday 14 December: 

10:00-11:00 - Australian Advantage for Clinical Trials – SA Government and Key Industry Stakeholders
The Innovation Workshop will explain why South Australia is an easy choice for clinical trials. You will learn about the different parts required for the conduct of your trial from government initiatives to all service required: clinical sites, ethics, project management, R&D Tax, data management.


11:30-12:30 - Brexit and Beyond: Recruiting Overseas Talent
This session will help employers navigate a shifting immigration landscape by providing an overview of the EU Settlement Scheme and the new points based system.

Speaker: Meghan Vozila


13:30-14:30 - Planning for Success – Insight Into 2021 Public Markets 
A session to understand the current market dynamic, the impact of the Covid-19 crisis or change at the White House. This is an essential session for companies to prepare for the Capital Markets as well as individuals to prepare for the next investment trends. It should review what is expected from capital markets and cover some perspectives on what the difference between the USA and the UK / Europe may be.


Tuesday 15 December: 

10:00-11:00 - Local Pharmaceutical Development Services - What Do You Need to Minimise Time to the Clinic for Your Small Volume Parenteral Presentations?


11:30-12:30 - How Much Water Do You EAT Everyday?
KIWAME stands for KIdney WAter MEasurement, and is a solution that addresses chronic kidney diseases patients at high risk of overhydration,  providing a personalized coaching application with the ultimate goal of improving their quality of life: a tailor-made monitoring kit to assess the body water volume, the nutrition and the daily activity

Speaker: Claudia Pandolfo, Researcher at Engineering Ingegneria Informatica


13:00-14:00 - Innovation to Deliver Sustainable Consistent Reagents From Research Through to Clinic
Having a single reagent that fulfils all necessary requirements from research through to the clinic, including discovery, development, scale-up and manufacturing can be a significant challenge. Having an experienced partner who can quickly understand any limitations and address them with innovative, customized solutions is imperative to success.

In this workshop, hear Abcam’s in-house antibody and protein experts discuss how innovation can make a real difference and accelerate success, and result in an end-to-end offering that delivers high-quality, sustainable reagents that meet desired target requirements and applications.








Media Sponsor